Key Insights Significant control over BioNTech by private equity firms implies that the general public has more ...

The BioNTech SE ADR BNTX rallied 3.82% to $120.21 Monday, on what proved to be an all-around mixed trading session for the ...

Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $145.00.

The BioNTech SE ADR BNTX inched 0.42% higher to $115.79 Friday, on what proved to be an all-around great trading session for ...

BioNTech SE (NASDAQ:BNTX – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the seventeen ...

Tidal Investments LLC lessened its stake in BioNTech SE (NASDAQ:BNTX – Free Report) by 39.5% in the third quarter, according ...

The German drugmaker will pay the NIH $791.5 million, while the University of Pennsylvania will get up to $467 million ...

The global pediatric vaccine market is set for unprecedented growth, with a valuation of US$ 54,130.1 million in 2023, ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...